Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 4, 2026
[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)]Shoichi Itoh, Miyako Satouchi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 21, 2024
[Current Status and Issues of Companion Diagnostics for Non-Small Cell Lung Cancer]Miyako Satouchi
Respiratory Investigation|March 1, 2020
The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patientsMiho Tanaka, Yoshihiro Hattori, Tatsuya Ishii, et al.
Internal Medicine (Tokyo, Japan)|September 24, 2025
Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 SkippingYuichiro Yasuda, Yoshihiro Hattori, Miyako Satouchi
Cancer Treatment and Research Communications|June 24, 2022
Psychological states regarding adjuvant chemotherapy in patients with non-small cell lung cancerTakahiro Mimae, Miyako Satouchi, Morihito Okada
Internal Medicine (Tokyo, Japan)|November 5, 2025
Successful Rechallenge of Trastuzumab Deruxtecan Following Early Detection of ILD in a Patient with Non-small Cell Lung Carcinoma Harboring HER2 Exon 20 InsertionYuichiro Yasuda, Yoshihiro Hattori, Miyako Satouchi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 28, 2018
[Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events]Miyako Satouchi, Makoto Nishio, Toyoaki Hida, et al.
BMC Cancer|February 13, 2020
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancerYoshihiro Hattori, Yuko Kono, Shoichi Itoh, et al.
Cancer Treatment and Research Communications|February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancerKoichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.
Lung Cancer (Amsterdam, Netherlands)|April 16, 2024
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trialSeiji Niho, Jun Sato, Miyako Satouchi, et al.
Pageof 15